Welcome to our dedicated page for Kalvista Pharm SEC filings (Ticker: KALV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) SEC filings page on Stock Titan brings together the company’s official disclosures as filed with the U.S. Securities and Exchange Commission. These documents provide structured insight into KalVista’s financial condition, governance, capital structure and key events related to its development and commercialization of EKTERLY (sebetralstat), an oral plasma kallikrein inhibitor for hereditary angioedema (HAE).
Investors can review Form 8‑K current reports in which KalVista announces material events, such as FDA approval of EKTERLY, preliminary and quarterly financial results, appointments of new executives and directors, and the issuance of 3.250% Convertible Senior Notes due 2031. These filings describe terms of financing arrangements, board and committee changes, executive employment agreements and stock‑based inducement awards.
Proxy materials such as the DEF 14A definitive proxy statement detail corporate governance matters, including annual meeting agendas, director elections, advisory votes on executive compensation and auditor ratification. They also outline board structure, committee responsibilities and stockholder voting procedures. Periodic reports referenced in the proxy statement, such as the company’s Annual Report on Form 10‑K, provide audited financial statements and broader business discussion.
Through Stock Titan, users can access these filings as they are made available on EDGAR and use AI‑powered summaries to interpret complex sections, including descriptions of convertible note covenants, events of default, change‑in‑control provisions and compensation arrangements. The filings page is also a key source for tracking any future Forms 3, 4 and 5 that would report insider transactions in KalVista common stock, as well as 10‑Q and 10‑K reports that update on revenue from EKTERLY, research and development spending and liquidity.
By reviewing KalVista’s SEC filings with the help of AI explanations, investors can better understand how the company finances its operations, governs its business and discloses risks and opportunities associated with its rare‑disease portfolio.
KalVista Pharmaceuticals’ major shareholder funds reported open-market sales of 214,631 shares of Common Stock. The transactions were executed on March 25–26 at prices between approximately $16.95 and $19.12 per share through entities affiliated with Venrock Healthcare Capital Partners.
After these sales, the affiliated funds continue to hold about 5,089,354 shares indirectly. The filing clarifies that management entities and individuals associated with these funds may be deemed to beneficially own these securities only to the extent of any indirect pecuniary interest.
KalVista Pharmaceuticals filed a Transition Report on Form 10-KT for the eight-month fiscal transition period May 1, 2025 through December 31, 2025, noting a change in fiscal year end to December 31. The company launched EKTERLY® (sebetralstat) after FDA approval on July 3, 2025 and lists additional approvals in the E.U., U.K., Switzerland, Japan, Australia and Singapore. KalVista states it began U.S. and German commercial operations, has established regional partnerships and entered a royalty financing arrangement providing an upfront $100.0 million plus a $22.0 million one-time payment. Cash and cash equivalents were $229.3 million as of December 31, 2025, and shares outstanding were 51,222,487 as of March 18, 2026.
KalVista Pharmaceuticals reported results for the eight-month transition period ended December 31, 2025, reflecting its shift to a calendar fiscal year. The company generated $49.1 million in global net product revenue from EKTERLY, the first and only oral on-demand treatment for hereditary angioedema.
Adoption is highlighted by 1,702 US patient start forms from launch through February and launches in markets including Germany and Japan through partner Kaken. Despite this growth, KalVista reported a net loss of $109.5 million and basic and diluted net loss per share of $2.03 for the period.
On the balance sheet, cash, cash equivalents and marketable securities were $300.2 million as of December 31, 2025, with total assets of $335.4 million and total liabilities of $338.1 million, resulting in a modest stockholders’ deficit. Management reiterated plans to expand EKTERLY access and advance pediatric filings.
KalVista Pharmaceuticals CEO Benjamin L. Palleiko reported routine equity compensation activity and a related tax sale. On March 6, 2026, he exercised 15,625 Restricted Stock Units (RSUs), receiving an equal number of KalVista common shares for no cash consideration. The RSUs vest in 16 equal quarterly installments starting June 6, 2024, subject to continued service. On March 9, 2026, he sold 6,693 common shares at a weighted average price of $16.0814 per share solely to cover tax withholding obligations from the RSU vesting, described as a non-discretionary “sell to cover” transaction. After these transactions, he holds 451,815 common shares directly and 125,001 RSUs, giving him a substantial ongoing equity stake.
KalVista Pharmaceuticals chief medical officer Paul K. Audhya reported a mix of equity award vesting and tax-related share sales. He exercised and settled restricted stock units (RSUs) into 6,250 and 5,000 shares of common stock at no cost on separate days, reflecting routine equity compensation vesting where each RSU converts into one share.
To cover tax withholding from these RSU settlements, he sold 5,354 shares of common stock in an open-market "sell to cover" transaction at a weighted average price of $15.5668 per share, described as non-discretionary. After these transactions, he held 138,983 shares of common stock directly, with RSU awards continuing to vest in equal sixteenth installments on each quarterly anniversary of the vesting commencement date.
KalVista Pharmaceuticals CEO Benjamin L. Palleiko reported a mix of RSU vesting and tax-related share sales. On February 21, 2026, he acquired 23,250 shares of Common Stock at $0.00 per share through the settlement of Restricted Stock Units, each RSU converting into one common share at no cost.
On February 23, 2026, he sold 10,034 shares of Common Stock at a weighted average price of $15.5668 per share, in transactions ranging from $15.5253 to $15.566982. According to the disclosure, this sale was a mandatory “sell to cover” to satisfy tax withholding obligations tied to the RSU vesting, and was not a discretionary trade.
KalVista Pharmaceuticals’ Chief Development Officer Christopher Yea reported RSU vesting, share issuance, and a related tax sale of common stock. On February 21 and 22, RSUs covering a total of 6,875 restricted stock units were exercised into the same number of common shares for no cash consideration.
Following these conversions, Yea conducted an open‑market "sell to cover" transaction on February 23, disposing of 4,347 common shares at a weighted average price of $15.5668 per share solely to satisfy tax withholding obligations tied to the RSU vesting. After these transactions, he held 226,701 common shares and 28,125 RSUs directly, with future RSU vesting scheduled in quarterly installments.
KalVista Pharmaceuticals Chief Commercial Officer Nicole Sweeny reported RSU vesting and related share movements. She acquired 6,250 and 5,000 shares of common stock on derivative exercises of restricted stock units at a price of $0.0000 per share. Each RSU represents a right to receive one share of common stock, with 1/16th of the award vesting on each quarterly anniversary of the vesting commencement date, subject to continued service.
On a separate transaction, she sold 3,975 shares of common stock in an open-market sale at a weighted average price of $15.5668 per share, in multiple trades between $15.5101 and $15.566982. The filing states this sale was a "sell to cover" to satisfy tax withholding obligations arising from RSU vesting and was not a discretionary transaction. Following these transactions, she directly held 47,003 shares of KalVista common stock.
KalVista Pharmaceuticals Chief Financial Officer Brian Piekos reported RSU vesting and a related tax sale. On February 21, 2026, he acquired 5,000 shares of Common Stock at $0.00 per share through the exercise and settlement of 5,000 Restricted Stock Units, each RSU converting into one share for no consideration. On February 23, 2026, he sold 1,767 shares of Common Stock in open-market transactions at a weighted-average price of $15.5668 per share to cover tax withholding obligations under a non-discretionary sell-to-cover arrangement. Following these transactions, he directly held 13,762 shares of Common Stock and 60,000 RSUs.
KalVista Pharmaceuticals chief executive officer Benjamin L. Palleiko reported routine equity compensation activity. On February 17, he exercised 2,419 restricted stock units, each converting into one share of common stock for no cash consideration, and his common stock holdings increased to 430,705 shares.
On February 18, he sold 1,038 common shares at $15.00 per share solely to cover tax withholding obligations related to the RSU vesting, a non‑discretionary “sell to cover” transaction. After this tax sale, he directly owned 429,667 common shares and 2,419 RSUs subject to continued vesting in equal quarterly installments.